Related Experiment Videos
[Autoimmune hemolysis after Catergen ([+]-cyanidanol-3)]
K Neftel1, A Fontana, M Guggenheim
1Medizinische Klinik, Universitätsspital, Zürich.
Schweizerische Medizinische Wochenschrift
|November 14, 1987
Summary
Catergen therapy can cause autoimmune hemolysis through drug-dependent antibodies or IgG autoantibodies. Hemolysis rapidly improved after discontinuing Catergen, supporting its role in these cases.
Area of Science:
- Hematology
- Immunology
- Pharmacology
Context:
- Investigating adverse effects of Catergen medication.
- Analyzing clinical and serological data in patients experiencing autoimmune hemolysis.
Purpose:
- To report and compare clinical and serological data of 5 autoimmune hemolysis cases linked to Catergen.
- To evaluate Catergen as a causative agent in drug-induced autoimmune hemolytic anemia.
Summary:
- Five cases of autoimmune hemolysis following Catergen treatment were analyzed.
- Rapid remission of hemolysis occurred within 2.5 to 10 weeks after Catergen withdrawal.
- Catergen may induce drug-dependent antibodies and long-term IgG autoantibodies against red blood cells.
Impact:
- Highlights the potential of Catergen to induce autoimmune hemolysis.
- Provides evidence for Catergen's role in drug-induced hemolytic anemia.
- Suggests monitoring for hemolysis in patients on long-term Catergen therapy.